BridgeBio (BBIO.US) heart disease therapy acoramidis outperforms Pfizer Inc. (PFE.US) competitor drug in real-world study

BridgeBio Pharma (BBIO.US) announced on Wednesday that its heart disease therapy acoramidis (branded as Attruby in the U.S.) outperformed Pfizer Inc.'s (PFE.US) competitor drug tafamidis (branded as Vyndamax in the U.S.) in a real-world study. In November 2024, the U.S. Food and Drug Administration (FDA) approved Attruby for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). This is a rare heart disease affecting 300,000 to 500,000 people worldwide, and Pfizer Inc. (PFE.US) dominates this field with Vyndamax. BridgeBio, citing peer-reviewed data, said acoramidis was associated with a 34% reduction in a composite measure of clinical worsening events, a reduction that was both statistically and clinically significant. The composite measure included events such as intensification of diuretic therapy, and increased diuretic use is one of the early indicators of worsening heart failure. The findings, published in the medical journal Cardiology and Therapy, were based on U.S. Medicare claims data and included 170 patients who started acoramidis and 448 patients who started tafamidis, spanning the period from December 2024 to April 2025. These patients were followed through July 2025, with a mean follow-up of approximately 4.6 months. The company plans to present additional real-world data at a medical conference in the fall to further demonstrate the advantages of acoramidis over acoramidis.